Advertisement
Organisation › Details
OSE Immunotherapeutics S.A.
OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. OSE Pharma’s lead product, Tedopi®, combines 10 “neo-epitopes” directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients. OSE Pharma is also planning a new Phase II clinical trial in combination with another immunotherapy treatment in NSCLC. Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or “neo- epitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN : FR0012127173 ; Mnémo : OSE). *
Start | 2014-09-21 existent | |
End | 2016-05-31 merged | |
Group | OSE Immunotherapeutics (Group) | |
Today | OSE Pharma S.A. | |
Predecessor | Effimune SAS | |
Industry | Memopi® multi-epitope technology | |
Industry 2 | Tedopi® cancer immunotherapy | |
Person | Poirier, Nicolas (OSE Immunotherapeutics 202210– CEO + CSO before CSO before Effimune + Tcl Pharma) | |
Person 2 | Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997) | |
Region | Nantes | |
Country | France | |
Street | 22 boulevard Benoni Goullin | |
City | 44200 Nantes | |
Tel | +33-2-2829-1010 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Profit | -5,584,000 (2015-12-31) | |
Cash | 15,131,000 (2015-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-05-22 |
Advertisement
More documents for OSE Immunotherapeutics (Group)
- [1] Boehringer Ingelheim. (5/22/24). "Press Release: Boehringer Ingelheim and OSE Immunotherapeutics Expand Collaboration to Develop First-in-class Treatments for Cancer and Cardio-renal-metabolic Diseases". Ingelheim & Nantes....
- [2] iOmx Therapeutics AG. (9/5/23). "Press Release: iOmx Therapeutics Appoints Dr. Nils Peter Debus as Chief Business Officer". Martinsried....
- [3] OSE Immunotherapeutics S.A.. (10/7/22). "Press Release: OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer". Nantes....
- [4] OSE Immunotherapeutics S.A.. (2/12/20). "Press Release: OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico". Nantes....
- [5] OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top